tetano
Editor, Senior Moderator
J Hematol
. 2022 Apr;11(2):77-80.
doi: 10.14740/jh845. Epub 2022 Apr 22.
COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma
Daniele Colombo[SUP] 1 [/SUP], Arianna Gatti[SUP] 2 [/SUP], Patrizia Alabardi[SUP] 1 [/SUP], Daniela Bompane[SUP] 1 [/SUP], Giorgio Bonardi[SUP] 1 [/SUP], Nicola Mumoli[SUP] 3 [/SUP], Paola Faggioli[SUP] 1 [/SUP], Pierangelo Clerici[SUP] 2 [/SUP], Bruno Brando[SUP] 2 [/SUP], Antonino Mazzone[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) can have a severe course in immunocompromised hosts and patients with hematological malignancies. In some cases, the bad prognosis is associated with the lack of B lymphocytes, with impaired antibody production and inefficient viral clearance. We report a case of a 67-year-old woman with a story of non-Hodgkin lymphoma treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), who got a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while being totally depleted of B cells. This condition has determined a severe and prolonged course of COVID-19, with persistently positive nasopharyngeal molecular swabs and lack of anti-SARS-CoV-2 specific antibodies. The clinical recovery was favored by the administration of convalescent hyperimmune plasma.
Keywords: Anti-SARS-CoV-2 antibodies; COVID-19; Convalescent plasma; Rituximab; SARS-CoV-2 swab.
. 2022 Apr;11(2):77-80.
doi: 10.14740/jh845. Epub 2022 Apr 22.
COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma
Daniele Colombo[SUP] 1 [/SUP], Arianna Gatti[SUP] 2 [/SUP], Patrizia Alabardi[SUP] 1 [/SUP], Daniela Bompane[SUP] 1 [/SUP], Giorgio Bonardi[SUP] 1 [/SUP], Nicola Mumoli[SUP] 3 [/SUP], Paola Faggioli[SUP] 1 [/SUP], Pierangelo Clerici[SUP] 2 [/SUP], Bruno Brando[SUP] 2 [/SUP], Antonino Mazzone[SUP] 1 [/SUP]
Affiliations
- PMID: 35573753
- PMCID: PMC9076145
- DOI: 10.14740/jh845
Abstract
Coronavirus disease 2019 (COVID-19) can have a severe course in immunocompromised hosts and patients with hematological malignancies. In some cases, the bad prognosis is associated with the lack of B lymphocytes, with impaired antibody production and inefficient viral clearance. We report a case of a 67-year-old woman with a story of non-Hodgkin lymphoma treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), who got a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while being totally depleted of B cells. This condition has determined a severe and prolonged course of COVID-19, with persistently positive nasopharyngeal molecular swabs and lack of anti-SARS-CoV-2 specific antibodies. The clinical recovery was favored by the administration of convalescent hyperimmune plasma.
Keywords: Anti-SARS-CoV-2 antibodies; COVID-19; Convalescent plasma; Rituximab; SARS-CoV-2 swab.